Discovery of a Highly Potent and Selective MEK Inhibitor: GSK1120212 (JTP-74057 DMSO Solvate).
about
Development of Therapeutics That Induce Mitochondrial Biogenesis for the Treatment of Acute and Chronic Degenerative Diseases.Concomitant oral and intravenous pharmacokinetics of trametinib, a MEK inhibitor, in subjects with solid tumoursTrametinib modulates cancer multidrug resistance by targeting ABCB1 transporterThe synthesis of Bcr-Abl inhibiting anticancer pharmaceutical agents imatinib, nilotinib and dasatinib.Targets, structures, and recent approaches in malignant melanoma chemotherapy.Modular Assembly of Allosteric MEK Inhibitor Structural Elements Unravels Potency and Feedback-Modulation Handles.Non-canonical PI3K-Cdc42-Pak-Mek-Erk Signaling Promotes Immune-Complex-Induced Apoptosis in Human Neutrophils.Identification and characterization of a novel chemotype MEK inhibitor able to alter the phosphorylation state of MEK1/2.Small-Molecule Screens: A Gateway to Cancer Therapeutic Agents with Case Studies of Food and Drug Administration-Approved Drugs.MEK inhibition induces apoptosis in osteosarcoma cells with constitutive ERK1/2 phosphorylation.Bioactivation of cyclopropyl rings by P450: an observation encountered during the optimisation of a series of hepatitis C virus NS5B inhibitors.Evaluation of the effects of food on the single-dose pharmacokinetics of trametinib, a first-in-class MEK inhibitor, in patients with cancer.Current Development Status of MEK Inhibitors.Using Genome Sequence to Enable the Design of Medicines and Chemical Probes.A modified gene trap approach for improved high-throughput cancer drug discovery.Suppressive effect of an orally active MEK1/2 inhibitor in two different animal models for rheumatoid arthritis: a comparison with leflunomide.MEK inhibitors for the treatment of NRAS mutant melanomaImidazolium Chloride: An Efficient Catalyst for Transamidation of Primary Amines
P2860
Q34538482-AEB11879-FD7F-425F-BC6A-98F2A9F9F793Q34571039-720CC470-C3E5-42BE-838E-7F9F410FE455Q36021057-41440B0D-6D22-4C5E-975B-7F347666A69DQ38068109-517764A9-DD4A-4D90-B1A6-841609171869Q38129832-EFBEFB3C-F3AE-485F-B2C1-66907C32A010Q38821763-9F4621B4-F2C0-40A6-9CED-854432E6E1DBQ40516211-A55E7A03-81F8-4673-B0FD-E79661663A18Q41916599-A2D99A2A-DC65-4887-9EB5-B418A6734E14Q42116442-5A6FA8F1-7985-4F10-9D15-C127A291F111Q42748194-DE3F6294-E4D2-4027-8BFA-9FDACC65B77BQ45324155-B2E295D3-B5A2-4D9D-B699-281E3073D8F0Q45340366-C8D6BBE1-2044-490F-B1EE-E21B066B6200Q47735535-5858560D-C4DD-4196-A544-91A908EE8216Q48263612-EDD10071-94BE-4DCE-981E-49D91495F21CQ52714926-33EAEA8F-E0F9-41CC-AF98-6251B532F7B2Q54536252-D4793DEC-21B0-4D90-9BD8-8CF916787209Q56889985-54CDC6EB-3523-4492-AEC5-CF5565B25924Q58691874-F571BFE0-2D25-4E33-B56B-E0F8ABC78CD7
P2860
Discovery of a Highly Potent and Selective MEK Inhibitor: GSK1120212 (JTP-74057 DMSO Solvate).
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Discovery of a Highly Potent a ...... 0212 (JTP-74057 DMSO Solvate).
@en
Discovery of a Highly Potent and Selective MEK Inhibitor: GSK1120212
@nl
type
label
Discovery of a Highly Potent a ...... 0212 (JTP-74057 DMSO Solvate).
@en
Discovery of a Highly Potent and Selective MEK Inhibitor: GSK1120212
@nl
prefLabel
Discovery of a Highly Potent a ...... 0212 (JTP-74057 DMSO Solvate).
@en
Discovery of a Highly Potent and Selective MEK Inhibitor: GSK1120212
@nl
P2093
P2860
P356
P1476
Discovery of a Highly Potent a ...... 0212 (JTP-74057 DMSO Solvate).
@en
P2093
Aidan G Gilmartin
Hironori Kurachi
Hiroyuki Abe
Hisashi Kawasaki
Johei Sakamoto
Junya Kakegawa
Katherine G Moss
Katsuya Maeda
Kazuhide Hayakawa
Koji Matsumura
P2860
P304
P356
10.1021/ML200004G
P577
2011-02-28T00:00:00Z